Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study
Drug Safety · 2026
DOI: 10.1007/s40264-026-01686-2 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Drug Safety, 2026. Verfasst von Sigal Kaplan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Teva Pharmaceutical Industries Ltd., 12 Hatrufa St, Netanya, Israel. Sigal.kaplan@teva.co.il. Hauptthemen laut MEDLINE: Modafinil, Pregnancy Outcome, Abnormalities, Drug-Induced, Prenatal Exposure Delayed Effects. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Cephalon.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Epidemiology, Teva Pharmaceutical Industries Ltd., 12 Hatrufa St, Netanya, Israel. Sigal.kaplan@teva.co.il.
- IQVIA, Real World Data, Paris, France.
Förderung
- Cephalon
Zitieren
APA
Kaplan, S., de Nascimento, J., & Contini, A. (2026). Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study. Drug Safety. https://doi.org/10.1007/s40264-026-01686-2
Vancouver
Kaplan S, de Nascimento J, Contini A. Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study. Drug Safety. 2026. doi:10.1007/s40264-026-01686-2
BibTeX
@article{Kaplan2026,
author = {Kaplan, Sigal and de Nascimento, Julie and Contini, Andrea},
title = {Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort Study},
journal = {Drug Safety},
year = {2026},
doi = {10.1007/s40264-026-01686-2}
}
EUVIMED